ETON (Eton Pharmaceuticals) Short Interest

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ETON Eton Pharmaceuticals Inc ETON
57 GF Score
Price $58.51
GF Value $19.98
Valuation Significantly Overvalued
! 3 Warning Signs
View Full Analysis

What is Eton Pharmaceuticals Short Interest?

Short Interest can be expressed as a percentage by dividing the number of shares sold short by the total number of outstanding shares.

Due to the license agreement change with our data vendor, Short Interest related data on GuruFocus will no longer be updated. Existing data will remain as-is, while new data will not be available, except for certain Australian and Canadian stocks.

ETON vs COLL, ALVO, PCRX: Short Interest Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Eton Pharmaceuticals's Short Interest, along with its competitors' market caps and Short Interest data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Eton Pharmaceuticals Short Interest vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Eton Pharmaceuticals's Short Interest distribution charts can be found below:

* The bar in red indicates where Eton Pharmaceuticals's Short Interest falls into.


ETON
57GF Score
Eton Pharmaceuticals Inc ETON
Short Interest is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Eton Pharmaceuticals (ETON) Overvalued in 2026?

Based on GuruFocus' analysis, Eton Pharmaceuticals stock appears to be overvalued. The current stock price of $58.51 is trading 192.8% above its estimated GF Value™ of $19.98. GuruFocus considers Eton Pharmaceuticals to be Significantly Overvalued.

Key valuation signals for ETON:

  • Short Interest:
  • GF Value™: $19.98 vs. price of $58.51 (192.8% above fair value)
  • GF Score™: 57/100 with 3 warning signs

No single metric tells the full story. See the ETON stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Eton Pharmaceuticals Business Description

Address 21925 West Field Parkway, Suite 235, Deer Park, IL, USA, 60010-7278
Eton Pharmaceuticals Inc is a United States based specialty pharmaceutical company. The company is engaged in developing and commercializing pharmaceutical products to fulfill an unmet patient need. It has eight commercial rare disease products, INCRELEX, ALKINDI SPRINKLE, KHINDIVITM, GALZIN, PKU GOLIKE, Carglumic Acid, Betaine Anhydrous and Nitisinone. It also has five additional product candidates in late-stage development: ET-600, Amglidia, ET-700, ET-800 and ZENEO hydrocortisone autoinjector.
57GF Score

Get the complete analysis for ETON

Short Interest is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$58.51
Price
$19.98
GF Value